JC virus in saliva, oropharyngeal fluid, blood, and urine samples obtained from 58 human immunodeficiency virus-infected persons and 58 matched controls was investigated by performing quantitative polymerase chain reaction. JC virus was rarely present in oropharyngeal fluid and blood samples, even in those obtained from immunosuppressed individuals, but it was commonly detected in urine samples from both groups, suggesting that urine contributes to transmission.
JC virus is widely distributed throughout the world. By 10 years of age, 40%-60% of the population is JCV seropositive [1] [2] [3] , and by adulthood, the rate may exceed 90% [2] . The mode of transmission of this virus is unknown; no acute disease has been associated with infection. An appreciation of the mechanisms of viral transmission, sites of latency, re-expression, and trafficking into the brain are fundamental to understanding the pathogenesis of progressive multifocal leukoencephalopathy (PML). The absence of an animal model for PML has precluded answers to these fundamental questions. The high frequency of JCV excretion in urine [4] [5] [6] [7] [8] [9] [10] [11] suggests the kidney as a site of viral latency; however, DNA sequences of the regulatory region of kidney or urine isolates are markedly different from those in the brains of patients with PML [12] . In situ DNA hybridization has demonstrated JC virus in B lymphocytes (PBLs) in bone marrow [13] and in other reticuloendothelial tissues (e.g., lung, spleen, lymph node [14, 15] , and tonsillar tissue [16] ).
The presence of JC virus DNA in tonsillar tissue and the frequency with which viruses are spread by the ororespiratory route suggests that JC virus is transmitted by these fluids. This study was undertaken to determine whether JC virus could be demonstrated in saliva and oropharyngeal secretions and whether its presence correlated with the presence of virus in PBLs and the degree of cellular immunosuppression, as determined by CD4 + T lymphocyte count. Methods. Fifty-eight HIV-seropositive subjects and 58 ageand sex-matched control subjects were recruited from the University of Kentucky (Lexington). All subjects were у18 years old. ELISA for HIV was performed on all controls. Saliva specimens, oropharyngeal washings, whole blood specimens, and urine samples were collected during the initial visit. Stimulated whole saliva samples (5 mL) were collected [17] . Throat washings were obtained by gargling with 10 mL of sterile saline for 15 s, followed by expectoration into a sterile tube. Samples were maintained on ice, divided into 1-mL aliquots, placed into bar code-labeled cryotubes, and frozen at Ϫ85ЊC.
Oropharyngeal fluid samples were concentrated using Qiagen columns (Qiagen), and nucleic acids were extracted from each specimen using the QIAamp Blood kit (Qiagen). DNA was analyzed with PCR using primers and probes for the large tumor antigen [18] . The JC virus probe was labeled at the 3 end with the quencher fluorochrome 6-carboxy-tetramethylrhodamine (PE Applied Biosystems). The 5 end of the probe was labeled with the reporter fluorochrome 6-carboxy-fluorescein. This primer-probe set reliably detects 1 copy of target DNA and is specific when tested with known polyomaviruses [18] .
Real-time PCR was used for the detection and quantification of JC virus in bodily fluids. Saliva samples (1 mL) and throat washings (2 mL) were centrifuged, and DNA was isolated from the cell pellet using the QIAamp DNA Mini Kit (Qiagen). DNA yield is typically 5-15 mg per 1 mL of saliva. Urine samples (2 mL) were concentrated using Centricon filters (Amicon), after which extraction was performed with QIAamp viral RNA Mini Kit (Qiagen). The buffy coats from 3 mL of blood were processed with a PUREGENE DNA Purification Kit (Gentra Systems). Each 50-mL PCR mixture contained 10 mL of purified DNA template in a final volume consisting of 1X TaqMan Universal PCR master mix (PE Applied Biosystems), 900-nm primers, and 250 nm of TaqMan probe. Real-time PCR was performed using an ABI Prism 7700 Sequence Detection system (PE Applied Biosystems). Cycling parameters were as follows: 50ЊC for 2 min, 95ЊC for 10 min, and 40 cycles at 95ЊC for 15 s and at 60 ЊC for 1 min. Each PCR run contained negative controls, including reaction mixtures without DNA template and several specimens that were known to contain no JC virus DNA. Positive controls included JC virus-positive DNA from a brain specimen obtained from a subject with PML, as well as a 10-fold dilution series ( Results. Table 1 shows the demographic characteristics of the study population. JC virus DNA was not amplified from saliva samples or throat washings obtained from any of the control subjects (table 2) nor from saliva samples obtained from the HIV-infected study population, but it was present in 2 (3.5%) of the throat washings obtained from HIV-infected population. Viral genome copy numbers were low for 1 subject (!50), but they exceeded 1,000,000 the other subject. Both patients had tonsils, but neither had evidence of oral mucosal pathology. Neither subject had JC virus in their PBLs. Their CD4 + cell counts were 434 and 331 cells/mm 3 , respectively. JC virus DNA was not amplified from the buffy coats of any of the control subjects and was present in only 1 HIV-seropositive subject (1.7%). Because there was concern about the efficiency of extraction of low molecular weight genomes from buffy coats using the PUREGENE DNA Purification Kit, a majority of samples (∼60) were processed in parallel using the QIAamp DNA Mini Kit. All buffy coats processed by the PURE-GENE method were negative for JC virus. JC virus DNA was detected in 1 buffy coat extracted with the Qiagen kit.
In contrast to the rarity of JC virus DNA in saliva, oropharyngeal fluids, and PBLs, JC virus was commonly detected in urine (tables 2 and 3). Among urine samples collected from the HIV-seronegative control population, 40 (70%) were positive for JC virus, with concentrations ranging from !50 to copies/mL (median concentration, 389 copies/mL). 95 ϫ 10 copies/mL) (table 4). Seven samples (12.1%) from the HIVseronegative group had concentrations that exceeded 100,000 copies/mL, whereas 13 (22.4%) of the samples from the HIVseropositive group exceeded 100,000 copies/mL ( ). There P p .14 was no statistically significant correlation between the presence of JC virus in bodily fluids and CD4 + cell count or HIV load. Age was a significant factor for the presence of JC virus, but only in the HIV-seronegative group. HIV-seronegative persons !29 years old were 24 times more likely to have JC virus DNA than persons 150 years old ( ; OR, 24; 95% CI, 3.36-P p .0015 171.53), and persons between 30 and 50 years old were 16.5 times more likely to have JC virus than were persons 150 years old ( ; OR, 16.5; 95% CI, 2.79-97.68). P p .002 Discussion. The composition of saliva and other oral fluids can reflect tissue fluid levels of infectious pathogens and are valuable sources for assessing and monitoring systemic disease. The latter have become more practical sources for assessment, with the appearance of increasingly sensitive assays.
DNA viruses are 1 type of numerous human pathogens detected in saliva and oropharyngeal fluids. Specifically, human herpesviruses [19] [20] [21] [22] [23] [24] , human papillomavirus [25] , and hepatitis B virus [26] have been detected by PCR in saliva and oral mucosal cells of persons with oral and systemic disease [27, 28] . In light of the seroepidemiological frequency of JC virus and its presence in tonsillar tissue [16, 29] , its presence in oropharyngeal fluids would not be unanticipated. However, we found that it was a very uncommon occurrence; it was present in none of the salivas sampled and in !4% of the throat wash- ings from our HIV-seropositive population. These results are in agreement with that of Swedish investigators [30] who did not detect JC virus DNA by PCR from either the saliva of 10 healthy adults or 60 HIV-seropositive adults or from nasopharyngeal aspirates of 201 children. Throat washings were not obtained in that study [30] . In this study, the presence of JC virus DNA in these fluids or PBLs did not correlate with the degree of immunosuppression, as assessed by determination of CD4 + cell count. The relative scarcity of subjects with JC virus DNA detectable in their throat washings precluded a meaningful statistical assessment of the importance of tonsils or oral pathology; however, both subjects who were positive also had their tonsils, and neither subject had any demonstrable oral mucosal disease.
In contrast, JC virus was detected in the urine of ∼70% of subjects in both groups. The median JC virus genome copy number was 3.4 times higher among subjects in the HIV-seropositive group. In contrast to other studies [8, 9] , JC virus detection in the urine was more common among younger subjects. In our study, no correlation was found between CD4 + cell count and JC virus copy number.
Our results suggest that JC virus re-expression in saliva and oropharyngeal fluids during viral latency is an unlikely source of infection. Rarely is the virus present in these fluids. Transmission may occur via this route during primary infection, but in the absence of a defined acute illness due to JC virus, demonstrating this will be difficult. The common worldwide detection of the virus in sewage and in 70% of urine samples collected from our study population more-strongly implicate the role of contaminated urine in human transmission than has been previously suggested [31] . However, the regulatory gene sequences of the JC virus isolated from urine requires deletions, substitutions, and duplications to mirror those observed in JC virus isolated from brain specimens from persons with PML [12, 31, 32] .
